RT Journal Article
T1 Intensive care medicine research agenda on invasive fungal infection in critically ill patients
A1 Bassetti, Matteo
A1 Garnacho-Montero, Jose
A1 Calandra, Thierry
A1 Kullberg, Bartjan
A1 Dimopoulos, George
A1 Azoulay, Elie
A1 Chakrabarti, Arunaloke
A1 Kett, Daniel
A1 Leon, Cristobal
A1 Ostrosky-Zeichner, Luis
A1 Sanguinetti, Maurizio
A1 Timsit, Jean-Francois
A1 Richardson, Malcom D.
A1 Shorr, Andrew
A1 Cornely, Oliver A.
K1 Candida
K1 Aspergillus
K1 Antifungals
K1 Echinocandins
K1 Fluconazole
K1 Beta-D-glucan
K1 Desorption-ionization-time
K1 Flight mass-spectrometry
K1 Combination antifungal therapy
K1 Liposomal amphotericin-b
K1 Blood-stream infections
K1 Germ tube antibody
K1 Beta-d-glucan
K1 Unit patients
K1 Aspergillus-fumigatus
K1 Icu patients
AB Purpose: To describe concisely the current standards of care, major recent advances, common beliefs that have been contradicted by recent trials, areas of uncertainty, and clinical studies that need to be performed over the next decade and their expected outcomes with regard to Candida and Aspergillus infections in non-neutropenic patients in the ICU setting.Methods: A systematic review of the medical literature taking account of national and international guidelines and expert opinion.Results: Severe invasive fungal infections (IFIs) are becoming increasingly frequent in critically ill patients. Approximately 80% of IFIs are due to Candida spp. and 0.3-19% to Aspergillus spp. Recent observations emphasize the necessity of building a worldwide sentinel network to monitor the emergence of new fungal species and changes in susceptibility. Robust data on the attributable mortality are essential for the design of clinical studies with mortality endpoints. Although early antifungal therapy for Candida has been recommended in patients with risk factors, sepsis of unknown cause, and positive Candida serum biomarkers [beta-1 -> 3-D-glucan (BDG) and Candida albicans germ tube antibody (CAGTA)], its usefulness and influence on outcome need to be confirmed. Future studies may specifically address the optimal diagnostic and therapeutic strategies for patients with abdominal candidiasis. Better knowledge of the pharmacokinetics of antifungal molecules and tissue penetration is a key issue for intensivists. Regarding invasive aspergillosis, further investigation is needed to determine its incidence in the ICU, its relationship with influenza outbreaks, the clinical impact of rapid diagnosis, and the significance of combination treatment.Conclusions: Fundamental questions regarding IFI have to be addressed over the next decade. The clinical studies described in this research agenda should provide a template and set priorities for the clinical investigations that need to be performed.
PB Springer
SN 0342-4642
YR 2017
FD 2017-09-01
LK http://hdl.handle.net/10668/18623
UL http://hdl.handle.net/10668/18623
LA en
DS RISalud
RD Apr 5, 2025